UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $198.28 and last traded at $198.28, with a volume of 80 shares. The stock had previously closed at $195.90.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $181.40 and a 200 day moving average price of $166.83.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- What Are Some of the Best Large-Cap Stocks to Buy?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Insider Trading – What You Need to Know
- 2 Drone Stocks Surging from Increased Media Attention
- How to invest in marijuana stocks in 7 steps
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
